ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom

Podcast Episodes
In this episode, listen to Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands.

Released: November 20, 2020

Expiration: November 19, 2021

Share

Faculty

Thomas Powles

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden

Michiel van der Heijden, MD, PhD

Medical Oncologist and Research Group Leader
Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, Netherlands

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD

Medical Oncologist and Research Group Leader
Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, Netherlands